Medevolve, Inc. – Trademark Portfolio
Entity Type: 03
Medevolve, Inc. has 11 U.S. trademark filings recorded with the United States Patent and Trademark Office (USPTO). Of these, 5 are successfully registered — a 45% registration rate. The portfolio includes marks such as MEDEVOLVE and EFFECTIVE INTELLIGENCE. Filings span 3 Nice Classification classes, with the highest activity in Class 42 (Computer & Scientific) and Class 9 (Computers & Electronics). This trademark owner is based in Little Rock, AR.
One Financial Center
Ste. 300 650 South Shackleford
Little Rock, AR 72211
Showing of trademarks Trademarks
Trademark Classifications
Medevolve, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does Medevolve, Inc. have?
Medevolve, Inc. has 11 U.S. trademarks filed with the USPTO. Of these, 5 registered, 2 abandoned, 4 cancelled.
What trademark classes does Medevolve, Inc. file in?
Medevolve, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 9 (Computers & Electronics), Class 35 (Advertising & Business). Class 42 covers scientific and technological services; industrial analysis and research services.
What are Medevolve, Inc.'s most well-known trademarks?
Medevolve, Inc.'s registered trademark portfolio includes well-known marks such as MEDEVOLVE and EFFECTIVE INTELLIGENCE. These are among 5 currently registered trademarks in the portfolio.
What is Medevolve, Inc.'s trademark registration success rate?
Medevolve, Inc. has a 45% trademark registration rate, with 5 out of 11 resolved applications resulting in successful registration. Currently, 0 applications are pending review.